Bris­tol My­ers un­corks pos­i­tive PhI­II read­out for sub­cu­ta­neous Op­di­vo

Bris­tol My­ers Squibb’s sub­cu­ta­neous for­mu­la­tion of its can­cer block­buster Op­di­vo proved non­in­fe­ri­or to in­tra­venous Op­di­vo in a Phase III tri­al, the com­pa­ny an­nounced on Thurs­day.

The study test­ed sub­cu­ta­neous Op­di­vo (nivolum­ab) in an open-la­bel tri­al for pa­tients with clear cell re­nal cell car­ci­no­ma (ccR­CC), though CMO Samit Hi­rawat has ex­pressed in­ter­est in ap­ply­ing the da­ta “to all oth­er in­di­ca­tions where Op­di­vo is used to­day as a sin­gle agent,” ac­cord­ing to an Al­phaSense tran­script of the com­pa­ny’s first-quar­ter earn­ings call.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER